2023
Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman A, Zalewski P, De Santis M, Armstrong A, Gerritsen W, Pachynski R, Saretsky T, Ghate S, Li X, Schloss C, Fizazi K. Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2023, 41: 129-129. DOI: 10.1200/jco.2023.41.6_suppl.129.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPatient-reported outcomesBPI-SF scoresBPI-SFTotal scoreWk 24Wk 27Castration-resistant prostate cancerPrespecified secondary end pointsEnd pointExploratory end pointsFACT-G totalPrespecified final analysisSecondary end pointsOverall improvement rateSubscale scoresMedian TTPPPain progressionData cutoffAgent therapyMedian timeAnalysis populationStudy treatmentSymptom scoresTrial arms
2013
Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial.
Small E, Higano C, Kantoff P, Whitmore J, Frohlich M, Petrylak D. Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. Journal Of Clinical Oncology 2013, 31: 74-74. DOI: 10.1200/jco.2013.31.6_suppl.74.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerSymptomatic metastatic castration-resistant prostate cancerCase report formsProtocol amendmentMedical reviewIMPACT trialCastration-resistant prostate cancerPrespecified secondary end pointsEnd pointECOG performance status 1Autologous cellular immunotherapyAverage pain scoreOpioid analgesic usePlacebo-treated patientsSecondary end pointsIndependent baseline predictorsPerformance status 1Objective disease progressionVisual analog scaleCox regression modelKaplan-Meier estimatesAsymptomatic ptsPrimary radiotherapyAnalgesic useCancer pain